Plan for Global Healthcare for All: Cheap Drugs Developed with “Virtual Clinical Trials” Revealed in Letter to Japanese Prime Minister

Here is a frightening letter that was discovered online today. It was addressed to the Japanese Prime Minister Shinzo Abe and was sent from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). The letter was signed by the IFPMA Executive Committee which includes the CEOs of the USA’s Eli Lilly ($24 billion in revenue in 2018), Japan’s Daiichi Sankyo ($8 billion in revenue in 2018), Belgium’s UCB ($27 billion in revenue in 2018) and France’s Sanofi ($42 billion in revenue in 2018). The letter was endorsed by the 30 or so IFPMA members that attended the Tokyo meeting with Abe that followed. The representatives (mostly the CEOs) of the global pharmaceutical corporations pictured are listed at the bottom of the letter. One of the alarming goals clearly proposed by the IFPMA and clearly stated in the letter to Prime Minister Abe is to make use of public medical information databases, IoT technology and virtual clinical trials “to reduce drug development time and costs and improve the probability of success”. Big Pharma shows that the future implementation of a plethora of dangerous, poorly evaluated drugs and vaccines that will no longer make use of actual randomized, double-blind, placebo-controlled, long-term clinical trials – and just use the more efficient, more cost-effective “virtual,” computer-based “studies.” Brave New World.